Pharmaceuticals, Biotechnology and Life Sciences
miDiagnostics, a POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for…
The startup company Novel Concepts Medical has announced that its novel plant-based treatment has resulted in successfully inhibiting the COVID-19…
AOP Orphan Pharmaceuticals announced that on Monday February 14, 2022 the German Federal Court of Justice decided on PEC’s challenge…
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate…
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of…
In the pharmaceutical industry, the issue of sustainability is increasingly coming into focus, forcing packaging manufacturers to rethink their strategies…
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today…
– Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix…
AstraZeneca has reported increase of revenue of 41% (38 at CER) to $37,417 million in results for Q4 and full year 2021 released on Thursday. This includes revenue from COVID-19 vaccine of $3,981 million. The increase of revenue has been driven by five medicines: Tagrisso ($5bn+), Farxiga ($3bn+), Lynparza ($2bn+), Calquence ($1bn+) and Fasenra ($1bn+).